Eli Lilly’s Revolutionary Weight Loss Drug Mounjaro Arrives in India

Global pharmaceutical giant Eli Lilly has made a major entry into the Indian market of healthcare by launching its breakthrough weight loss drug Mounjaro. India’s Central Drugs Standard Control Organisation (CDSCO) has recently approved the drug which would be used in obesity and type 2 diabetes drugs, to help prevent the booming health problems in these cases.

A Breakthrough in Weight Management

Tripeptide or Mounjaro is an emerging medication that works to help control people’s weight by activating GIP and GLP-1 hormone receptors. Unlike other weight loss treatments, it has two components of action targeting these receptors that are responsible for glucose regulation and appetite control in a manner that is never even observed in the existing treatments.

The drug is intended for use in adults whose body mass index (BMI) is 30 or more (obesity) or 27 or more (overweight) and who have additional weight related diseases such as hypertension or type 2 diabetes. The drug is part of a weight management program that includes a reduced calorie diet and an increased physical activity.

The Impact of Mounjaro on the Health of India

However, the seeming paradox of high rates of obesity and diabetes has monopolized news reports about India’s health in recent years as India, like several other countries, has been grappling with the dual burden of these chronic diseases. Diabetes is a problem that affects more than 100 million people in the country with obesity being a major risk that indicates heart disease, hypertension, and sleep apnea. In a timely intervention for millions looking for effective treatment, Eli Lilly’s Mounjaro is among several new drugs on the market.

Senior Medical Director at Eli Lilly Dr. Manish Mistry expressed pleasure over the launch and said that Mounjaro offers a unique solution for metabolic health management. He pointed out that the drug could considerably boost the quality of life of people who are suffering from these life limiting health conditions.

The Clinical Evidence Behind Mounjaro

Mounjaro’s clinical trials have turned out impressive. In the SURMOUNT-1 trial, people using Mounjaro and diet and exercise lost an average of 21.8 kg, with some patients losing up to 26.3 kg, compared to only 3.2 kg in the placebo group. In addition, the SURPASS program also showed Mounjaro reduced A1C levels in type 2 diabetes patients by as much as 2.4 percent, representing dramatic improvement in diabetes control.

Side Effects and Precautions

Mounjaro has proven to be effective in weight loss and control of type 2 diabetes however, like other medications, it has possible side effects. Common problems include gastrointestinal problems including nausea, vomiting, diarrhea and constipation, particularly during the early stages of treatment. Most of these effects are mild and go away as the body adjusts to the drug. But some patients have experienced more serious side effects of pancreatitis, hypoglycemia (low blood sugar) and problems with their gallbladders, with the formation of gallstones.

People who have had prior pancreatic or thyroid disorders and serious gastrointestinal issues are advised by experts to speak with their health care provider before taking Mounjaro. Those using insulin or other medications for diabetes are advised to regularly monitor to keep risks at a minimum.

A Step Toward a Healthier Future

The launch of Mounjaro in India is a step forward to solve the obesity and diabetics crisis in the country. While this new treatment option is being explored by healthcare providers and patients, the hope is that it will help play a role in improving long term health outcomes for millions of Indians. Awareness of Eli Lilly’s drug, and the availability and proper use of this promising drug, will depend on sharing the drug with the government and the medical community, and his commitment toward this will be essential.